KB 103

Drug Profile

KB 103

Alternative Names: KB103

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Krystal Biotech
  • Class Gene therapies; Skin disorder therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Epidermolysis bullosa

Most Recent Events

  • 27 Mar 2018 Krystal Biotech files an IND application with the US FDA for Epidermolysis bullosa
  • 16 Jan 2018 Krystal Biotech has patent protection for the use of herpes simplex virus vectors for prevention and treatment of skin disorders in USA
  • 13 Nov 2017 Recombinant DNA Advisory Committee grants clearance for phase I/II trial of KB 103 in Epidermolysis bullosa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top